BioMed Research International / 2016 / Article / Tab 5

Research Article

Lack of Association between Genetic Polymorphisms of JAK-STAT Signaling Pathway Genes and Acute Anterior Uveitis in Han Chinese

Table 5

Allele and genotype frequencies of SNPs in patients with AAU versus control subjects stratified by AS and HLA-B27 status.

Gene SNPAllele and genotypeAAU+AS+
HLA-B27
AAU+AS
HLA-B27
Control (AS+)Pc (AS+)OR (95% CI) (AS-)Pc (AS)OR (95% CI)

JAK1rs310241C205 (31.6%)119 (29.9%)392 (27.5%)0.05NS1.22 (1.00–1.49)0.32NS1.13 (0.88–1.45)
CC30 (9.3%)11 (5.5%)45 (6.3%)0.09NS1.52 (0.94–2.45)0.70NS0.87 (0.44–1.72)
CT145 (44.7%)97 (48.7%)302 (42.4%)0.47NS1.10 (0.85–1.44)0.10NS1.31 (0.95–1.79)
TT149 (46.0%)90 (45.7%)366 (51.3%)0.11NS0.81 (0.62–1.05)0.14NS0.79 (0.58–1.08)
rs2780815G543 (84.3%)335 (89.6%)1250 (87.5%)0.05NS0.77 (0.59–1.00)0.28NS1.22 (0.85–1.77)
GG230 (71.4%)151 (80.7%)548 (76.7%)0.07NS0.76 (0.56–1.02)0.24NS1.27 (0.85–1.90)
GT83 (25.8%)33 (17.6%)154 (21.6%)0.14NS1.26 (0.93–1.72)0.23NS0.78 (0.51–1.18)
TT9 (2.8%)3 (1.7%)12 (1.7%)0.24NS1.68 (0.70–4.03)0.94NS0.95 (0.27–3.42)

JAK2rs10758669A449 (66.2%)256 (65.3%)980 (69.0%)0.20NS0.88 (0.72–1.70)0.16NS0.85 (0.67–1.07)
AA139 (41.0%)81 (41.3%)346 (48.7%)0.02NS0.73 (0.56–0.95)0.07NS0.74 (0.54–1.02)
AC171 (50.4%)94 (48.0%)288 (40.6%)2.56 × 10−30.0841.49 (1.15–1.94)0.06NS1.35 (0.98–1.86)
CC29 (8.6%)21 (10.7%)76 (10.7%)0.28NS0.78 (0.50–1.22)1.00NS1.00 (0.60–1.67)
rs10975003C165 (25.7%)86 (22.5%)272 (21.2%)0.03NS1.29 (1.03–1.61)0.57NS1.08 (0.82–1.43)
CC18 (5.6%)8 (4.2%)28 (4.4%)0.39NS1.31 (0.71–2.40)0.92NS0.96 (0.43–2.14)
CT129 (40.2%)70 (36.6%)216 (33.5%)0.04NS1.33 (1.01–1.75)0.44NS1.14 (0.82–1.60)
TT174 (54.2%)113 (59.2%)399 (62.1%)0.01NS0.72 (0.55–0.95)0.47NS0.89 (0.64–1.23)

STAT1rs1547550C608 (88.1%)329 (85.7%)1254 (87.8%)0.84NS1.03 (0.78–1.36)0.26NS0.83 (0.60–1.15)
CC264 (76.5%)143 (74.5%)555 (77.7%)0.66NS0.93 (0.69–1.27)0.34NS0.84 (0.58–1.21)
CG80 (23.2%)43 (22.4%)144 (20.2%)0.26NS1.20 (0.88–1.63)0.50NS1.14 (0.78–1.68)
GG1 (0.3%)6 (3.1%)15 (2.1%)0.02NS0.14 (0.02–103)0.40NS1.50 (0.58–3.93)
rs2066802C130 (20.7%)60 (16.8%)288 (20.7%)0.99NS1.00 (0.79–1.26)0.09NS0.77 (0.57–1.05)
CC11 (3.5%)4 (2.2%)27 (3.9%)0.77NS0.90 (0.44–1.83)0.29NS0.57 (0.20–1.64)
CT108 (34.4%)52 (29.1%)234 (33.7%)0.82NS1.03 (0.78–1.37)0.24NS0.81 (0.56–1.16)
TT195 (62.1%)123 (68.7%)434 (62.4%)0.92NS0.99 (0.75–1.30)0.12NS1.32 (0.93–1.88)
rs6718902C368 (57.7%)216 (54.5%)778 (54.5%)0.18NS1.14 (0.94–1.38)0.98NS1.00 (0.80–1.25)
CC103 (32.3%)60 (30.3%)209 (29.3%)0.33NS1.15 (0.87–1.53)0.78NS1.05 (0.75–1.48)
CT162 (50.8%)96 (48.5%)360 (50.4%)0.91NS1.02 (0.78–1.32)0.63NS0.93 (0.68–1.27)
TT54 (16.9%)42 (21.2%)145 (20.3%)0.20NS0.80 (0.57–1.13)0.78NS1.06 (0.72–1.56)
rs10199181A170 (26.9%)100 (27.8%)397 (27.8%)0.67NS0.96 (0.77–1.18)0.99NS1.00 (0.77–1.29)
AA25 (7.9%)18 (10.0%)55 (7.7%)0.91NS1.03 (0.63–1.68)0.32NS1.33 (0.76–2.33)
AT120 (38.0%)64 (35.6%)287 (40.2%)0.50NS0.91 (0.69–1.20)0.26NS0.82 (0.58–1.15)
TT171 (54.1%)98 (54.4%)372 (52.1%)0.55NS1.08 (0.83–1.41)0.57NS1.10 (0.79–1.53)

IRF1rs2070721A221 (34.9%)135 (37.3%)487 (34.1%)0.73NS1.03 (0.85–1.26)0.25NS1.15 (0.90-1.46)
AA37 (11.7%)24 (13.3%)74 (10.4%)0.53NS1.14 (0.75–1.74)0.26NS1.32 (0.81–2.16)
AC147 (46.4%)87 (48.1%)339 (47.4%)0.74NS0.96 (0.73–1.25)0.89NS1.02 (0.74–1.42)
CC133 (42.0%)70 (38.6%)301 (42.2%)0.95NS0.99 (0.76–1.30)0.40NS0.97 (0.62–1.21)

NOS2
 
rs2297518A130 (19.0%)64 (16.5%)209 (16.2%)0.11NS1.22 (0.96–1.55)0.87NS1.03 (0.76–1.39)
AA7 (2.0%)5 (2.6%)12 (1.9%)0.83NS1.11 (0.43–2.84)0.53NS1.40 (0.49–4.02)
AG116 (33.9%)54 (27.8%)185 (28.6%)0.08NS1.28 (0.97–1.70)0.84NS0.96 (0.67–1.38)
GG219 (64.1%)135 (69.6%)450 (69.5%)0.07NS0.78 (0.59–1.03)0.99NS1.00 (0.71–1.42)
rs4795067
 
A512 (73.6%)295 (74.5%)1008 (76.1%)0.20NS0.87 (0.71–1.08)0.61NS0.92 (0.71–1.19)
AA184 (52.9%)109 (55.1%)382 (57.7%)0.14NS0.82 (0.63–1.07)0.51NS0.90 (0.65–1.24)
AG144 (41.4%)77 (38.8%)244 (36.9%)0.16NS1.21 (0.93–1.58)0.60NS1.09 (0.79–1.51)
GG20 (5.7%)12 (6.1%)36 (5.4%)0.84NS1.06 (0.60–1.86)0.74NS1.12 (0.57–2.20)

OR = odds ratio; 95% CI = 95% confidence interval.
Pc = value adjusted by Bonferroni correction.